Clinical Application of Anti-CCR4 Monoclonal Antibody - PubMed (original) (raw)

Review

doi: 10.1159/000431059. Epub 2015 Nov 10.

Affiliations

• PMID: 26550987
• DOI: 10.1159/000431059

Review

Clinical Application of Anti-CCR4 Monoclonal Antibody

Ryuzo Ueda. Oncology. 2015.

Abstract

Mogamulizumab (KW-0761) is a humanized anti-CCR4 monoclonal antibody with a defucosylated Fc region (Potelligent® Technology), which markedly enhances antibody-dependent cellular cytotoxicity by increasing its binding affinity to the Fcx03B3; receptor expressed on effector cells. It is an effective agent for patients with CCR4-positive adult T-cell leukemia and peripheral T-cell lymphoma, for which no standard therapy exists, and it has an acceptable toxicity profile. In addition, because CCR4 is expressed on CD45RA-FOXP3highCD4+ effector regulatory T (Treg) cells, it is an even more attractive target, because Treg cells involved in the tumor escape from host immunity in the tumor microenvironment. Based on this concept, we conducted a clinical study of mogamulizumab for the treatment of CCR4-negative advanced or recurrent solid cancer, with the aim of depleting effector Treg cells and thus boosting anti-cancer immune responses. In this study, mogamulizumab infusion at doses ranging from 0.1 to 1.0 mg/kg was safe and well tolerated. Four of 10 patients showed stable disease during treatment and showed long-term survival. Mogamulizumab efficiently depleted effector Treg cells even at the lowest dose of 0.1 mg/kg, and an augmentation or induction of specific immune responses to cancer/testis antigens was observed in some patients. In the near future, a novel immunotherapy targeting Treg cells with mogamulizumab will be offered to patients with different types of cancer.

© 2015 S. Karger AG, Basel.

PubMed Disclaimer

Similar articles

• Reduction of regulatory T cells by Mogamulizumab, a defucosylated anti-CC chemokine receptor 4 antibody, in patients with aggressive/refractory mycosis fungoides and Sézary syndrome.
  Ni X, Jorgensen JL, Goswami M, Challagundla P, Decker WK, Kim YH, Duvic MA. Ni X, et al. Clin Cancer Res. 2015 Jan 15;21(2):274-85. doi: 10.1158/1078-0432.CCR-14-0830. Epub 2014 Nov 5. Clin Cancer Res. 2015. PMID: 25376389
• Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-cc chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma.
  Ogura M, Ishida T, Hatake K, Taniwaki M, Ando K, Tobinai K, Fujimoto K, Yamamoto K, Miyamoto T, Uike N, Tanimoto M, Tsukasaki K, Ishizawa K, Suzumiya J, Inagaki H, Tamura K, Akinaga S, Tomonaga M, Ueda R. Ogura M, et al. J Clin Oncol. 2014 Apr 10;32(11):1157-63. doi: 10.1200/JCO.2013.52.0924. Epub 2014 Mar 10. J Clin Oncol. 2014. PMID: 24616310 Clinical Trial.
• Phase Ia Study of FoxP3+ CD4 Treg Depletion by Infusion of a Humanized Anti-CCR4 Antibody, KW-0761, in Cancer Patients.
  Kurose K, Ohue Y, Wada H, Iida S, Ishida T, Kojima T, Doi T, Suzuki S, Isobe M, Funakoshi T, Kakimi K, Nishikawa H, Udono H, Oka M, Ueda R, Nakayama E. Kurose K, et al. Clin Cancer Res. 2015 Oct 1;21(19):4327-36. doi: 10.1158/1078-0432.CCR-15-0357. Clin Cancer Res. 2015. PMID: 26429981 Clinical Trial.
• Mogamulizumab for the treatment of relapsed or refractory adult T-cell leukemia-lymphoma.
  Winsett FT, Lewis DJ, Duvic M. Winsett FT, et al. Expert Rev Hematol. 2017 Sep;10(9):757-760. doi: 10.1080/17474086.2017.1361819. Epub 2017 Aug 21. Expert Rev Hematol. 2017. PMID: 28756726 Review.
• Mogamulizumab and the treatment of CCR4-positive T-cell lymphomas.
  Remer M, Al-Shamkhani A, Glennie M, Johnson P. Remer M, et al. Immunotherapy. 2014;6(11):1187-206. doi: 10.2217/imt.14.94. Immunotherapy. 2014. PMID: 25496334 Review.

Cited by

• A Transcriptomic Analysis of Laryngeal Dysplasia.
  Maffini F, Lepanto D, Chu F, Tagliabue M, Vacirca D, De Berardinis R, Gandini S, Vignati S, Ranghiero A, Taormina S, Rappa A, Cossu Rocca M, Alterio D, Chiocca S, Barberis M, Preda L, Pagni F, Fusco N, Ansarin M. Maffini F, et al. Int J Mol Sci. 2024 Sep 7;25(17):9685. doi: 10.3390/ijms25179685. Int J Mol Sci. 2024. PMID: 39273632 Free PMC article. Review.
• The adaptor protein TRAF3 is an immune checkpoint that inhibits myeloid-derived suppressor cell expansion.
  Zhu S, Lalani AI, Jin J, Sant'Angelo D, Covey LR, Liu K, Young HA, Ostrand-Rosenberg S, Xie P. Zhu S, et al. Front Immunol. 2023 May 3;14:1167924. doi: 10.3389/fimmu.2023.1167924. eCollection 2023. Front Immunol. 2023. PMID: 37207205 Free PMC article.
• Frequency of Peripheral CD8+ T Cells Expressing Chemo-Attractant Receptors CCR1, 4 and 5 Increases in NPC Patients with EBV Clearance upon Radiotherapy.
  Mahajan S, Balcioglu HE, Oostvogels A, Dik WA, Chan KCA, Lo KW, Hui EP, Tsang A, Tong J, Lam WKJ, Wong K, Chan ATC, Ma BBY, Debets R. Mahajan S, et al. Cancers (Basel). 2023 Mar 21;15(6):1887. doi: 10.3390/cancers15061887. Cancers (Basel). 2023. PMID: 36980772 Free PMC article.
• CCR4 as a Therapeutic Target for Cancer Immunotherapy.
  Yoshie O. Yoshie O. Cancers (Basel). 2021 Nov 4;13(21):5542. doi: 10.3390/cancers13215542. Cancers (Basel). 2021. PMID: 34771703 Free PMC article. Review.
• Cyclophosphamide enhances the antitumor potency of GITR engagement by increasing oligoclonal cytotoxic T cell fitness.
  Hirschhorn D, Betof Warner A, Maniyar R, Chow A, Mangarin LM, Cohen AD, Hamadene L, Rizzuto GA, Budhu S, Suek N, Liu C, Houghton AN, Merghoub T, Wolchok JD. Hirschhorn D, et al. JCI Insight. 2021 Oct 22;6(20):e151035. doi: 10.1172/jci.insight.151035. JCI Insight. 2021. PMID: 34676831 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • S. Karger AG, Basel, Switzerland